Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570637 | 1.00 | EGFR (0.57) | EGFR | |
| SCHEMBL7573128 | 0.97 | EGFR (0.59) | EGFR | |
| SCHEMBL7004066 | 0.97 | EGFR (0.59) | EGFR | |
| SCHEMBL7565005 | 0.96 | EGFR (0.56) | EGFR | |
| SCHEMBL6998166 | 0.96 | EGFR (0.56) | EGFR | |
| SCHEMBL7006043 | 0.89 | EGFR (0.57) | EGFR | |
| SCHEMBL7566237 | 0.89 | EGFR (0.57) | EGFR | |
| SCHEMBL7101014 | 0.87 | EGFR (0.58) | EGFR | |
| SCHEMBL5226187 | 0.87 | EGFR (0.58) | EGFR | |
| SCHEMBL7224556 | 0.87 | EGFR (0.58) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082270-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082270-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.